Press release
The Drug-Resistant Tuberculosis Treatment Market To Show Impeccable Growth In The Forecast Period
According to the latest research by Persistence Market Research, the Drug-Resistant Tuberculosis Treatment market is set to witness a growth of 5% during 2021-2031. Demand for Drug-Resistant Tuberculosis Treatment expects to witness steady recovery in the short-term, with an optimistic growth outlook in the long run. The growing advancement for the Drug-Resistant Tuberculosis Treatment market industry will offer lucrative opportunities in near future.
The WHO has described the global effects of multidrug-resistant tuberculosis (MDR TB) as a "public health crisis". In 2013, an estimated 480,000 new cases and 210,000 deaths were caused by MDR TB which is defined by resistance to isoniazid and rifampin, the 2 most effective anti-TB drugs.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/32634
In addition, approximately 9% of MDR TB cases are believed to be extensively drug-resistant (XDR TB), which implies additional resistance to any fluoroquinolone and at least 1 injectable second-line drug. Treatment of MDR and XDR TB requires prolonged therapy with toxic, poorly tolerated medications, and for patients in developing countries, access to active drugs may be limited.
Drug-resistant TB is the largest single source of antimicrobial resistance in the world. According to WHO, approximately half a million people worldwide are diagnosed with multi-drug-resistant TB each year, and about 8.5% of those people have XDR TB.
Common TB treatments don't work on XDR TB, so people with this extreme form of the disease need to take a combination of around eight drugs for more than a year. This growing number of drug-resistant tuberculosis will act as a driver for drug-resistant tuberculosis treatment market growth in the forecasted period.
There has been continuous research going on in the drug-resistant tuberculosis treatment field. FDA is actively involved in the approval of the related drugs. For instance, in Aug 2019, FDA Approves Pretomanid for Highly Drug-Resistant Forms of Tuberculosis. This continuous R&D will attract the market in the forecasted period.
Request for Table of Content@ https://www.persistencemarketresearch.com/toc/32634
North America held the majority of the revenue share of the global market in 2020. There has been a significant increase in the number of cases of MDR-TB in the United States. Although cases of MDR-TB have been reported from many areas of the country, the majority of the cases are concentrated in large urban areas.
MDR-TB is difficult and expensive to treat. CDC has developed a National Action Plan to Combat Multidrug-Resistant Tuberculosis. The U.S. has large support from government and insurance providers to facilitate the healthcare system. As the cell therapy treatment are expensive the favorable healthcare system of the region will promote the growth of the market in the forecasted period. Besides being a developed nation clinical trials are going on in the region facilitating the adoption of cell therapy.
Asia is the second-largest market for drug-resistant tuberculosis treatment. According to WHO, it is estimated that 171,000 Rifampicin-resistant (RR) and multi-drug-resistant TB (MDR-TB) cases accounting for more than 35% of global burden appeared in the region in 2019, of which around 70,000 were started on second-line treatment in the same year.
Six out of the 30 high TB (and MDR-TB) burden countries are in the region are Bangladesh, the Democratic People's Republic of Korea, India, Indonesia, Myanmar, and Thailand. Central Asia accounts for 85% of the tuberculosis incidence and more than 90% of drug-resistant tuberculosis cases emerging in the region. This huge prevalence of MDR and XDR in the region will give rise to a drug-resistant tuberculosis treatment market in the forecasted period.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/32634
Some of the key players of Drug-Resistant Tuberculosis Treatment include,
Sanofi
Novartis AG
Endo International plc
CMP Pharma
STI Pharma LLC
Akorn Incorporated
Lupin
Johnson & Johnson Services Inc.
Macleods Pharmaceuticals Ltd
Pfizer Inc
Hikma Pharmaceuticals PLC
Lannett
Mylan N.V.
Teva Pharmaceutical Industries Ltd
Fresenius Kabi AG
Complete Report Details@ https://www.persistencemarketresearch.com/market-research/drug-resistant-tuberculosis-treatment-market.asp
Key Segments
By Drug Class
Amoxicillin/Clavulanate
Bedaquiline
Carbapenems with Clavulanic Acid
Clofazimine
Cycloserine
Delamanid
Ethambutol
Ethionamide and Prothionamide
Fluoroquinolones
Levofloxacin
Moxifloxacin
Ciprofloxacin
Ofloxacin
Linezolid
Macrolides
Azithromycin
Clarithromycin
p-Aminosalicylic Acid
Pyrazinamide
By Disease Type
Multidrug-Resistant TB (MDR TB)
Extensively Drug-resistant TB (XDR TB)
By Treatment Type
First-Line Anti-TB Drugs
Second-Line Anti-TB Drugs
Others
By Distribution channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Others
Related Reports:
Rosacea Therapeutics Market - https://www.persistencemarketresearch.com/market-research/rosacea-treatment-market.asp
Pressure Relief Devices Market - https://www.persistencemarketresearch.com/market-research/pressure-relief-devices-market.asp
Contact Us:
Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com
Website - https://www.persistencemarketresearch.com
About Us:
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers' experience by acting as the "missing" link between "customer relationships" and "business outcomes'. The best possible returns are assured therein.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The Drug-Resistant Tuberculosis Treatment Market To Show Impeccable Growth In The Forecast Period here
News-ID: 2660511 • Views: …
More Releases from Persistence Market Research
Frozen Foods Market Heats Up with Innovation and Growing Consumer Demand
Market Overview:
The frozen foods market consists of a wide range of products, including frozen fruits and vegetables, meat and seafood, ready-to-eat meals, and desserts. These products are preserved through freezing to maintain freshness and quality for an extended period.
Market Size and Growth:
The global market for frozen foods is forecasted to be of valuation US$ 281.0 Billion in the year 2022 which is expanding at a value CAGR of 5.1% and…
The Global Graphene Market's Striking Growth and Innovative Applications
Introduction
Graphene, a single layer of carbon atoms arranged in a hexagonal lattice, has gained global recognition for its extraordinary properties, such as exceptional electrical and thermal conductivity, mechanical strength, and flexibility. Since its isolation in 2004 by Andre Geim and Konstantin Novoselov, graphene has sparked considerable interest in both scientific and industrial communities. This report explores the current state of the graphene market and its potential growth opportunities.
Get Access To…
Business Opportunities in Cyber Security Mesh Market : Top Countries Data Analys …
Market Overview:
The projected global market size for cyber security mesh is expected to reach $8.8 billion by the year 2033, with an estimated valuation of $1.2 billion by 2023. This market is poised to experience a compound annual growth rate (CAGR) of 21.7% from 2023 to 2033.
The global Cyber Security Mesh market is poised for significant growth as organizations worldwide grapple with the escalating threat landscape. Cybersecurity has become an…
Synthetic Beta-Carotene Market To Boost Incredible Growth: 2033, Share Valuation …
Key market trends included a shift towards natural and plant-based ingredients, as consumers sought cleaner labels and healthier options. This drove the demand for naturally sourced beta-carotene, but synthetic beta-carotene still had its place due to its cost-effectiveness and consistency in production. The market was also influenced by regulatory changes and evolving dietary preferences, which affected the application and formulation of synthetic beta-carotene in various products.
To obtain the latest market…
More Releases for Drug
Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions.
Alcohol abuse and drug…
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.
Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes…
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Hepatitis Disease
1.1 Prologue
1.1.1 History of Hepatitis
1.1.2 Causes of Hepatitis Disease
1.2 Types of Viruses which are Responsible for Hepatitis Disease
2. Global Prevalence of Hepatitis Infection
3. Available Drug Classes for Hepatitis Disease Treatment
3.1 Interferon Alfa Therapy
3.2 Protease Inhibitors Therapy
3.3 Polymerase…
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Indispensable Advent of Microcapsules
1.1 Trajectory of Microencapsulation
1.2 Why and wherefores for Microencapsulation
2. Characterization of Microcapsules
2.1 Composition of Microcapsules
2.2 Parameters Influencing Microcapsules
3. Engineering Technology of Microcapsules
3.1 Physical Manufacturing Technologies
3.2 Physicochemical and Chemical Technologies
4. Applicability of Microcapsules
4.1 Microcapsules in Pharmaceuticals
4.2 Microcapsules in Nutraceuticals
…
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug
European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning…
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June.
The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug…
